SAB Biotherapeutics, Inc.
SABS
$3.70
-$0.05-1.33%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.20% | -11.91% | -137.10% | 549.32% | -94.62% |
| Total Depreciation and Amortization | 10.84% | -1.39% | -0.29% | -1.06% | -0.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.17% | -7.38% | 110.47% | -4,989.16% | 128.03% |
| Change in Net Operating Assets | 257.36% | 71.84% | -550.60% | 72.28% | -11.46% |
| Cash from Operations | 31.04% | 14.93% | -28.55% | -82.45% | 8.26% |
| Capital Expenditure | -61.26% | -5.37% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -63.64% | -- | -- | -100.00% | 0.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 94.90% | -8,265.67% | 99.40% | -2,598.73% | 11.28% |
| Cash from Investing | 92.56% | -3,747.60% | 98.69% | -2,598.49% | 11.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.21% | -1.91% | -1.94% | 79.32% | -1.28% |
| Issuance of Common Stock | -97.32% | -- | -100.00% | 168,729,700.00% | -- |
| Repurchase of Common Stock | 4.35% | -6.98% | 12.24% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.37% | 215,738.13% | -100.02% | 97,047.70% | 0.00% |
| Foreign Exchange rate Adjustments | 629.93% | 103.69% | -961.07% | -120.89% | 322.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -222.32% | 152.94% | -173.53% | 1,420.02% | 40.16% |